SEC Comment Letter 0000000000-26-001915 to Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc.
Date: Feb. 24, 2026 · CIK: 0001781983 · Accession: 0000000000-26-001915
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293609
Letter
February 24, 2026 Oren Gilad President and Chief Executive Officer Aprea Therapeutics, Inc. 3805 Old Easton Road Doylestown, PA 18902 Re:Aprea Therapeutics, Inc. Registration Statement on Form S-3 Filed February 20, 2026 File No. 333-293609 Dear Oren Gilad: We have conducted a limited review of your registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form S-3 General 1.We note that you filed this registration statement more than 45 days after the end of your fiscal year. As such, you do not appear to meet the age of financial statement requirements of Rule 8-08(b) of Regulation S-X. Please revise to include audited financial statements for the fiscal year ended December 31, 2025. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.
February 24, 2026 Page 2 Please contact Alan Campbell at 202-551-4224 or Joe McCann at 202-551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Patrick O’Malley, Esq.
Show Raw Text
February 24, 2026
Oren Gilad
President and Chief Executive Officer
Aprea Therapeutics, Inc.
3805 Old Easton Road
Doylestown, PA 18902
Re:Aprea Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 20, 2026
File No. 333-293609
Dear Oren Gilad:
We have conducted a limited review of your registration statement and have the
following comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Registration Statement on Form S-3
General
1.We note that you filed this registration statement more than 45 days after the end of your
fiscal year. As such, you do not appear to meet the age of financial statement
requirements of Rule 8-08(b) of Regulation S-X. Please revise to include audited
financial statements for the fiscal year ended December 31, 2025.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
February 24, 2026
Page 2
Please contact Alan Campbell at 202-551-4224 or Joe McCann at 202-551-6262 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Patrick O’Malley, Esq.